Results 221 to 230 of about 48,216 (304)

Condoms [PDF]

open access: yesReproductive Health Matters, 2007
openaire   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie   +10 more
wiley   +1 more source

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi   +3 more
wiley   +1 more source

Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Vincristine‐induced peripheral neuropathy (VIPN) is a common side effect in children and adolescents treated with vincristine. Assessing VIPN, especially in young children, is challenging due to a lack of sensitive tools. This limits our understanding of the nature and risk factors of VIPN. This study aimed to investigate neurofilament light chain
Peter Erik Lotko Pontoppidan   +8 more
wiley   +1 more source

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance.
Kimitoshi Nakamura   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy